Beyond Air, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Beyond Air, Inc. on February 16, 2021. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Garden City, NY. Its common stock trades on The Nasdaq Stock Market LLC under the symbol "XAIR".
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figure disclosed is a grant award of up to $2.17 million.
Material Changes
On February 16, 2021, the Company received a grant of up to $2.17 million from the Cystic Fibrosis Foundation. This funding is designated to advance the clinical development of inhaled nitric oxide for the treatment of Nontuberculous Mycobacteria pulmonary disease.
Outlook, Risks, and Management Commentary
Management highlighted the grant as a significant step in advancing the clinical development of its therapeutic candidate. The filing does not contain updated financial guidance, specific risk factors, or details on contingencies beyond the standard disclosure of the grant event.
Investor Verification Checklist
- Verify the terms and milestones associated with the $2.17 million Cystic Fibrosis Foundation grant.
- Review the attached Press Release (Exhibit 99.1) for detailed clinical development timelines.
- Check subsequent filings for the impact of this grant on the Company's cash position and burn rate.
- Confirm the status of the inhaled nitric oxide program for Nontuberculous Mycobacteria pulmonary disease.